CELG Related Options
-
Celgene (CELG) volatility up; shares down 10% on withdrawal of Revlimid CHMP submission
-
Goldman Sachs Recommends Buying Options Ahead of Healthcare Conference
-
Celgene (CELG) calls active on solid Q1 results
-
Celgene (CELG) options active as shares sell off 8% on revlimid data
-
Celgene (CELG) volatility flat at 40; into $2.8B acquisition of Abraxis
-
Celgene (CELG) volatility decreases as shares rally off lows
-
Celgene (CELG) calls active after recent sell off
-
Equity option family volume leaders in first 30-minutes of Trading: AAPL, WM, MEDX, CELG
-
Equity option family volume leaders in first 30-minutes of Trading: AAPL CELG C RIO
-
Celgene (CELG) volatility decreases after $2.9 billion PHRM purchase
-
Equity option family volume leaders in first 30-minutes of Trading: AAPL MSFT BEAS CELG
-
Most active equity option families in first 30-minutes of Trading: GM RIMM AAPL SEPR PALM CELG C
-
American Society of Clinical Oncology (ASCO) participants June stock option implied Volatility
-
Celgene (CELG) June option implied volatility of 59 is above average into Events
-
Most active equity option families in first 30-minutes of Trading: AV C CELG INTC CMCSK AMAT ADBE XOM VLO AET
-
Celgene-CELG implied volatility at 58 prior to FDA approval of Revlimid
Back to CELG Stock Lookup
